Chain Bridge I 10-Q quarterly reports

Chain Bridge I's latest quarterly report reveals a significant working capital deficit and continued uncertainty regarding its business combination, raising substantial doubt about its ability to continue as a going concern.

Chain Bridge I reports a net loss of $436,659 for Q1 2026 while continuing to pursue a business combination with Phytanix Bio.

Chain Bridge I, a SPAC, reported a significant net loss, a worsening accumulated deficit, and faces delisting from OTCQB, raising substantial doubt about its ability to continue as a going concern after its business combination agreement with Phytanix Bio was terminated.

Chain Bridge I filed an amended quarterly report, restating financials due to accounting errors, revealing a material weakness in internal controls, and announcing the termination of its business combination with Phytanix Bio, leading to Nasdaq delisting.

Chain Bridge I, a SPAC, reported a Q2 2025 net income but terminated its business combination agreement with Phytanix Bio, raising substantial doubt about its ability to continue as a going concern.

Chain Bridge I, a blank check company, reported a net loss of $363,640 for Q1 2025, terminated its business combination agreement with Phytanix Bio, and continues to face significant liquidity challenges and delisting from Nasdaq, raising substantial doubt about its ability to continue as a going concern.

Chain Bridge I's Q3 2024 report reveals a net income of $624,000, but also highlights substantial doubt about the company's ability to continue as a going concern due to its upcoming mandatory liquidation date.

Chain Bridge I (CBRG) reports a net loss for the second quarter of 2024 and announces a business combination agreement with Phytanix Bio, extending its operational deadline to November 15, 2024.

Chain Bridge I's Q1 2024 report reveals a net loss and going concern uncertainty as it seeks a business combination by November 2024.